Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only losers are watching as we move up, up, up...with BIG NEWS on Monday from what l was told from a little bird we should blow by .05....again why people sit and whine with their finger in their butt is behond me...come have happy, happy, happy days with the ones in the know...
Wouldn't you love to know....lol...happy, happy, happy days...
Rumor is we are move to a new exchange in the new year...sweet$$$$$
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison
C.TRYP | 1 hour ago
Tryp has partnered with Paul Hutson, PharmD and Christopher Nicholas, PhD to advance the Company's proprietary, psilocybin-based drug product
San Diego, California--(Newsfile Corp. - October 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company's proprietary drug product, TRP-8803.
Dr. Hutson and Dr. Nicholas will serve as Investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803 in healthy, volunteer patients. The completion of the studies will provide further regulatory support for TRP-8803 as well as insight into the pharmacokinetic profile of TRP-8803. TRP-8803 is expected to be used in Tryp's Phase 2b studies and eventual commercialization as the Company develops the product for chronic pain indications such as fibromyalgia and phantom limb pain, among other diseases.
Dr. Hutson is Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy and brings years of experience assessing the therapeutic uses of psilocybin and other psychoactive medications to the partnership. Dr. Hutson has been prolific in evaluating blood exposure levels of psilocybin-based products in patients and the impact on patients as the Principal Investigator for a safety and dose escalation clinical trial for psilocybin performed at the University of Wisconsin-Madison. Dr. Hutson also serves as Director of the University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances in the University of Wisconsin School of Pharmacy.
Commenting on the collaboration, Dr. Hutson said, "I am excited to work with Tryp to assess the unique features of their proprietary drug product, TRP-8803. Psilocybin-based treatments have incredible clinical potential. Our collaboration will explore important safety and dosing considerations with the potential to create a best-in-class psychedelic therapy with significant benefits to patients across a wide range of indications."
Trained as a clinical psychologist and neuroscientist, Dr. Nicholas is Assistant Professor at the University of Wisconsin School of Medicine and Public Health where he serves as the Principal Investigator on a number of psilocybin clinical trials and mechanistic studies. With expertise in psychedelic-assisted therapy, he will provide guidance on study design, behavioral and biological outcome measures, and psychological support to ensure participants will successfully complete the pharmacology study. "I'm hopeful that TRP-8803 will not only be an effective treatment modality, but one that also improves access to care and scalability."
"We are fortunate to benefit from Dr. Hutson's and Dr. Nicholas's tremendous expertise in psilocybin-based treatments and their effects on patients," said Jim Gilligan, PhD, President and Chief Scientific Officer of Tryp Therapeutics. "TRP-8803 has the potential to set the standard in safety, control, and patient comfort for psilocybin-based therapies. We look forward to working with Dr. Hutson and Dr. Nicholas on this exciting endeavor."
About Tryp Therapeutics
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information, please visit www.tryptherapeutics.com.
Investor Inquiries:
Joseph Green
Edison Group
investors@tryptherapeutics.com
Media Inquiries:
Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797
Lol...here comes the gap at $1.20...OUCH!!!
We need to hear about the $$$ from this second shipment...thinking it will be Monday....happy so happy....
What happened to your support floor...a delisting may happen sooner then we all thought...
NEW ALL TIME LOW...SAD SO SAD...HERE COMES THE GAP FILL AT $1.20 GET YOUR LUNCH MONEY OUT PEEPS...
How Psychedelics Changed My Life when you lost your life savings....sad so sad...how low will we go today..maybe fill that $1.20 gap?
Sell tomorrow and take your loss before you hurt someone... with the price dropping so fast we could be delisted by Christmas..sad so sad...
Long term support means absolutely no interest in this crap, so down we go first to fill the gap at $1.20 then delisted...sad so sad..
Scams tend to go lower and lower until they disappear..sad so sad...
Not until the gap at $1.20 is filled
Nice to see RED first thing in the morning again...maybe today we get closer to filling that gap at $1.20
Bummer another RED DAY...SAD SO SAD...
Yawn...another RED DAY...
Lol...hello $1.20 these guys are a joke...sad so sad..
Maybe this is a scam?
Come on down $1.20
Lol keep the news coming as we go lower and lower
Is RED a good sign for a stock day after day?
Don't worry about me because l am doing just fine with getting in at .09 to .11 in 2018..sold in the 4 to 5 range and reloading again....
To get delisted or to fill the gap at $1.20?
Lol...we still need to fill the gap at $1.20 so no party yet....what will come first delisting or $1.20 my bet is delisting....
Classic pump and dump here...sad, so sad...
New time lows coming as we desend down to the 1.20 gap...OUCH!!!!
Lol...they will do and say anything now to try to prevent a delisting...watch as another RED DAY falls upon you....sad, so sad.....
I see we are in the death spiral again....so maybe this time we will fill the gap at 1.20.....OUCH...sad so sad
Rolling correction or a sinking ship?
Its called delisting...
Is bad news getting leaked?
Lol...2.30 low already...maybe we can hit 2.15 today...is delisting coming?
Let's bring this down between 2.28 and 2.38....so that means another RED DAY....sad so sad...
OMG....bad news coming l hear...more RED days
I tried to warn my peeps...maybe next time you wont laugh...sad so sad...delisting is not to far off..
$2.42 OUCH!!!
$2.44...OUCH!!!..dropping fast to $1.20...sell now and buy back in at half the price peeps..
NEW LOW $2.47!!!but the question is how low will it go..maybe fill the gap at $1.20 this week?
Watch for new lows today...sad so sad...